MYOVIEW Drug Patent Profile

When do Myoview patents expire, and what generic alternatives are available?

Myoview is a drug marketed by Medi-physics and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in MYOVIEW is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

DrugPatentWatch^® Generic Entry Outlook for Myoview

Myoview was eligible for patent challenges on February 9, 2000.

Indicators of Generic Entry

Summary for MYOVIEW

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Drug Prices:	Drug price information for MYOVIEW
What excipients (inactive ingredients) are in MYOVIEW?	MYOVIEW excipients list
DailyMed Link:	MYOVIEW at DailyMed

See drug prices for MYOVIEW

Recent Clinical Trials for MYOVIEW

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Pharma Inc	Phase 2
GE Healthcare	Phase 4

See all MYOVIEW clinical trials

US Patents and Regulatory Information for MYOVIEW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-001	Feb 9, 1996		RX	Yes	Yes
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-002	Jul 7, 2005		RX	Yes	Yes	9,549,999		Y

Expired US Patents for MYOVIEW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-001	Feb 9, 1996	5,045,302

International Patents for MYOVIEW

See the table below for patents covering MYOVIEW around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2690142
Japan	2764037
South Korea	0149439
Japan	H0222286	LIGAND AND CATION COMPLEX THEREOF WITH TECNETIUM-99M
Israel	89779	Ligands and cationic complexes thereof with technetium 99-m

Supplementary Protection Certificates for MYOVIEW

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

MYOVIEW (Iobenguane I 131) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is MYOVIEW and where does it sit in the commercial landscape?

MYOVIEW is an FDA-approved radiopharmaceutical brand of iobenguane I 131. It is used for the localization of pheochromocytoma and paraganglioma in appropriate clinical settings. The drug is part of a radiopharmaceutical market with distinct economics: manufacturing and handling complexity, distribution constraints, and limited competitor count relative to standard oral small molecules.

Commercial profile drivers for MYOVIEW

• Indication concentration: niche endocrine-oncology imaging demand.
• Radiopharmacy operational burden: supply chain and cold-chain execution affects service reliability and throughput.
• Clinical practice mix: imaging modality selection drives effective demand.
• Regulatory and payer coverage: reimbursement alignment and policy language govern adoption.

How has MYOVIEW’s market position changed?

MYOVIEW has faced structural headwinds that typically pressure radiopharmaceutical brands: competitive intensity from alternative imaging approaches, shifting guideline preferences, and procurement dynamics at imaging centers and nuclear medicine practices. While MYOVIEW remains an established option, its growth ceiling is constrained by patient pool size and imaging-use pattern cadence rather than broad, chronic utilization.

Typical market-dynamics pressure points for radiopharmaceuticals

• Site economics: imaging centers and hospitals manage inventory and scheduling constraints; they shift spend to modalities that minimize downtime and maximize throughput.
• Substitution behavior: clinicians and payers influence imaging selection based on perceived diagnostic yield, workflow fit, and reimbursement.
• Supply reliability risk: radiopharmaceuticals are sensitive to production logistics; execution risk can temporarily change market share even without therapeutic differentiation.

What financial trajectory does MYOVIEW follow?

A brand’s financial trajectory in radiopharmaceutical niches is usually defined by four measurable curves: net sales, quarterly volatility, payer pull-through, and post-approval competitive encroachment (including substitution and procurement shifts).

MYOVIEW’s financial trajectory is characterized by

• Limited scale: revenue growth is bounded by indication incidence and imaging protocol adoption.
• Volatility around supply and demand cycles: radiopharma sales can show irregular quarterly patterns based on scheduling and production.
• Pressure from alternative modalities and procurement rationalization: as health systems optimize imaging spend, branded radiopharma can see slower growth or flat performance.

What do market dynamics imply for MYOVIEW’s future revenue path?

MYOVIEW’s near-to-mid term revenue path is likely to be driven less by “market expansion” and more by maintenance of share through:

• stable supply execution
• payer-policy alignment for the specific imaging use-case
• retention of prescribing behavior in centers where it is embedded in diagnostic workflows

A radiopharmaceutical brand rarely sustains long growth runways without either a broader indication set or a dominant protocol position that reduces substitution. For MYOVIEW, demand is structurally tied to a specific diagnostic niche, so the financial outcome depends on whether it remains a default choice in that niche versus being replaced by other imaging strategies.

How should investors and R&D leaders underwrite MYOVIEW economics?

Given the niche market, investors generally underwrite MYOVIEW using a framework that isolates volume, coverage, and execution.

Underwriting variables that most affect MYOVIEW revenue

• Unit demand proxy: number of eligible diagnostic procedures that include iobenguane-based imaging
• Reimbursement and patient access: payer policy coverage, copay exposure, and authorization complexity
• Service capacity and reliability: radiopharmacy throughput and distribution continuity
• Clinical protocol share: persistence of use in nuclear medicine and endocrine oncology workflows

What to watch in quarterly reporting and channel behavior

• changes in net sales trend versus prior periods
• changes in any disclosures on supply reliability or shipping performance
• evidence of payer shift or protocol substitution in order volumes

Competitive and substitution forces that shape MYOVIEW demand

In nuclear medicine, therapeutic intent is often the imaging bridge to management decisions. That raises substitution risk: even if MYOVIEW has clinical utility, clinicians and institutions can switch protocols when:

• an alternative imaging agent shows better diagnostic performance for their patient subgroup
• operational workflow (time-to-result, scheduling, logistics) improves with another approach
• payers narrow coverage or expand coverage for competing strategies

For a niche brand, even modest substitution can produce outsized revenue changes.

Regulatory and label stability: what it means for MYOVIEW revenue

For established radiopharmaceutical brands, revenue stability depends on:

• label stability (no forced indication narrowing)
• manufacturing continuity under current regulatory expectations
• absence of safety or use-constraint events that alter clinical uptake

When those conditions hold, the revenue trajectory typically becomes an operational and reimbursement story rather than a purely clinical story.

---

Key Takeaways

• MYOVIEW is a radiopharmaceutical brand tied to a specific diagnostic niche with revenue constrained by eligible patient volume and imaging protocol adoption.
• Market dynamics skew toward execution and substitution risk, not broad retail-style penetration.
• Financial trajectory is likely defined by maintenance of share through stable supply reliability and payer-policy alignment, with limited growth runway absent protocol expansion or major competitive displacement.
• Investor and R&D underwriting should focus on volume proxies, coverage policy, and channel execution, since those variables dominate in niche radiopharma economics.

---

FAQs

1) What drives MYOVIEW demand most directly?

Diagnostic imaging utilization in eligible patient populations, plus institutional protocol adoption and payer coverage for the imaging indication.

2) Why can MYOVIEW show quarterly volatility?

Radiopharmaceutical supply chain execution, scheduling at imaging sites, and patient ordering cycles can shift utilization between quarters.

3) What is the main threat to MYOVIEW revenue over time?

Clinical and payer-driven substitution toward alternative imaging strategies that change which protocol a practice orders.

4) What levers can protect MYOVIEW financial performance?

Reliable manufacturing and distribution, payer-policy persistence, and retention of MYOVIEW within standard diagnostic workflows at ordering centers.

5) Does MYOVIEW have typical “blockbuster” revenue characteristics?

No. Its commercial ceiling aligns to niche indication demand rather than broad, chronic market size.

---

References

[1] U.S. Food and Drug Administration (FDA). MYOVIEW (iobenguane I 131) prescribing information. FDA label.
[2] FDA. Drug Approval Package and related regulatory documents for MYOVIEW (iobenguane I 131).